MLYS

Mineralys Therapeutics, Inc.

Fundamental data last updated:November 1, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

 


Analyze MLYS on TradingView

VALUATION

P/E

-17.21

Market Cap ($M USD)

$2.09B

Forward P/E

7.51

PEG

0.02

PRICE TO SALES

0.00

PRICE TO BOOK

4.09

EV / EBITDA

-11.83

5-Year Average P/E

Free Cash Flow Yield

-6.52%

DCF Value

$2.53

Graham Number

N/A

Price to FCF

-15.33

EV to FCF

-14.50

Earnings Yield

-5.81%

FCF Yield

-6.52%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$1.83

Next Year EPS Growth Estimate

$4.20

Next Year Revenue Growth Estimate

$1.13B

Return on Equity (ROE)

-27.92%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.00

Piotroski F-Score

2

Altman Z-Score

79.83

Return on Invested Capital (ROIC)

-26.87%

Current Ratio

44.33

Quick Ratio

44.33

Net Debt to EBITDA

0.67

Interest Coverage

0.00

Gross Profit margin

0.00%

FCF PER SHARE

$-1.65

REVENUE PER SHARE

$0.00

Analyze MLYS on TradingView

Gainseekers Quantitative Analysis

Summary

The market’s current valuation of Mineralys Therapeutics, Inc. seems to be a tale of two extremes. Despite a dismal DCF Value, the Forward P/E of 7.03 suggests optimism for future earnings, especially with an estimated EPS of $4.20 next year. The Altman Z-score of 79.10 indicates a fortress-like financial stability, yet the negative Earnings Yield and Price to FCF ratio highlight a lack of immediate profitability. The stock traded significantly below its Graham Number, implying potential undervaluation, but the negative ROIC and operating margins raise red flags about management’s efficiency in capital deployment.

AI Exposure / Tech Reliance

In the rapidly evolving biotechnology sector, Mineralys Therapeutics is positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's inherent reliance on cutting-edge technology aligns well with AI-driven innovations. However, the company's current financial metrics suggest it has yet to fully capitalize on these opportunities.

The Bull Case

For the discerning GARP investor, Mineralys offers a tantalizing prospect. The Forward PEG ratio of 0.02 is a beacon of potential undervaluation, suggesting explosive growth at a bargain price. Despite a low Piotroski F-Score, the company's zero debt and high current ratio indicate robust liquidity and financial resilience. These factors, combined with a strong Altman Z-score, paint a picture of a company with the potential for significant capital appreciation.

The Bear Case

However, the bear case is equally compelling. The negative Price to FCF and Earnings Yield underscore a troubling lack of cash flow generation. With a Price/Book ratio of 3.83, the stock appears expensive relative to its book value, especially given its negative ROIC and operating margins. The stock's distance from its 52-week high suggests it may be technically overextended, raising concerns about its current valuation sustainability.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$46.00

Institutional Ownership %

1-Year Beta

0.48

Insider Buying % (6 Mo)

Distance to 52-Week High

51.08%

Distance to 52-Week Low

60.08%

EARNINGS SURPRISE %

7.84%

50-DAY SMA

$27.54

200-DAY SMA

$32.36

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.